<code id='77F8A1458F'></code><style id='77F8A1458F'></style>
    • <acronym id='77F8A1458F'></acronym>
      <center id='77F8A1458F'><center id='77F8A1458F'><tfoot id='77F8A1458F'></tfoot></center><abbr id='77F8A1458F'><dir id='77F8A1458F'><tfoot id='77F8A1458F'></tfoot><noframes id='77F8A1458F'>

    • <optgroup id='77F8A1458F'><strike id='77F8A1458F'><sup id='77F8A1458F'></sup></strike><code id='77F8A1458F'></code></optgroup>
        1. <b id='77F8A1458F'><label id='77F8A1458F'><select id='77F8A1458F'><dt id='77F8A1458F'><span id='77F8A1458F'></span></dt></select></label></b><u id='77F8A1458F'></u>
          <i id='77F8A1458F'><strike id='77F8A1458F'><tt id='77F8A1458F'><pre id='77F8A1458F'></pre></tt></strike></i>

          leisure time

          leisure time

          author:comprehensive    Page View:1994
          Nasdaq
          Mario Tama/Getty Images

          Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

          The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

          advertisement

          The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more
          Gilead acquiring CymaBay and its liver disease drug for $4.3 billion
          Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

          YichuanCao/SipaUSAGileadSciencessaidMondayitwillacquireCymaBayTherapeuticsfor$4.3billion,addinganewt

          read more
          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more

          For Medicare Advantage, Democrats want stronger protections around AI

          Sen.ElizabethWarren(D-Mass.)KentNishimura/GettyImagesSenateDemocratsonThursdaysaidMedicareshouldtake